OptiNose
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well … Read more
OptiNose (OPTN) - Total Liabilities
Latest total liabilities as of March 2025: $176.22 Million USD
Based on the latest financial reports, OptiNose (OPTN) has total liabilities worth $176.22 Million USD as of March 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OptiNose - Total Liabilities Trend (2015–2024)
This chart illustrates how OptiNose's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
OptiNose Competitors by Total Liabilities
The table below lists competitors of OptiNose ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Northwest Bancorp
NASDAQ:FNWB
|
USA | $1.95 Billion |
|
Hsin Yung Chien Co Ltd
TW:2114
|
Taiwan | NT$597.24 Million |
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
USA | $11.62 Million |
|
CONPET SA
RO:COTE
|
Romania | RON136.04 Million |
|
Syncom Formulations (India) Limited
NSE:SYNCOMF
|
India | ₹775.88 Million |
|
Daejoo Inc
KQ:003310
|
Korea | ₩26.38 Billion |
|
Yesco Holdings Co. Ltd
KO:015360
|
Korea | ₩705.09 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down OptiNose's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OptiNose's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OptiNose (2015–2024)
The table below shows the annual total liabilities of OptiNose from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $169.15 Million | -12.96% |
| 2023-12-31 | $194.34 Million | -3.24% |
| 2022-12-31 | $200.85 Million | +6.92% |
| 2021-12-31 | $187.84 Million | +3.20% |
| 2020-12-31 | $182.03 Million | +63.89% |
| 2019-12-31 | $111.07 Million | +12.90% |
| 2018-12-31 | $98.38 Million | +13.55% |
| 2017-12-31 | $86.64 Million | +90.88% |
| 2016-12-31 | $45.39 Million | +5.17% |
| 2015-12-31 | $43.16 Million | -- |